Sage Therapeutics Company Profile (NASDAQ:SAGE)

About Sage Therapeutics (NASDAQ:SAGE)

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SAGE
  • CUSIP: N/A
  • Web: www.sagerx.com
Capitalization:
  • Market Cap: $2.34906 billion
  • Outstanding Shares: 37,441,000
Average Prices:
  • 50 Day Moving Avg: $80.26
  • 200 Day Moving Avg: $74.83
  • 52 Week Range: $38.30 - $90.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.13
  • P/E Growth: 0.77
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.96 per share
  • Price / Book: 9.04
Profitability:
  • EBIDTA: ($222,350,000.00)
  • Return on Equity: -64.86%
  • Return on Assets: -59.43%
Debt:
  • Current Ratio: 9.02%
  • Quick Ratio: 9.02%
Misc:
  • Average Volume: 553,039 shs.
  • Beta: 2.94
  • Short Ratio: 15.21
 

Frequently Asked Questions for Sage Therapeutics (NASDAQ:SAGE)

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($1.88) EPS for the quarter, missing the consensus estimate of ($1.63) by $0.25. During the same period last year, the company posted ($1.08) EPS. View Sage Therapeutics' Earnings History.

Where is Sage Therapeutics' stock going? Where will Sage Therapeutics' stock price be in 2017?

13 analysts have issued 12 month target prices for Sage Therapeutics' shares. Their forecasts range from $60.00 to $117.00. On average, they expect Sage Therapeutics' stock price to reach $86.77 in the next year. View Analyst Ratings for Sage Therapeutics.

What are analysts saying about Sage Therapeutics stock?

Here are some recent quotes from research analysts about Sage Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "We hosted a call with expert Dr. Peter Kaplan to review the super refractory status epilepticus (SRSE) space and expectations for Sage Therapeutics’ drug IV brexanolone, which is currently being evaluated in the ongoing pivotal Phase 3 STATUS trial (results expected 3Q17). Dr. Kaplan has been practicing at Johns Hopkins for 30 years and his academic experience has been mostly clinical in nature. He is currently based at Johns Hopkins Bayview Medical Center and is consulted throughout the hospital for input regarding EEGs and for optimal management of status epilepticus. Below we highlight our key takeaways from the call." (6/13/2017)
  • 2. BMO Capital Markets analysts commented, "We spoke with two leading psychiatrists who agreed that these data, while early, look great; they were particularly impressed with the magnitude of effect, early onset, strong remission rate, and overall safety for SAGE-217 in MDD. This profile is considered the 'holy grail' in treating depression. The physicians were also very optimistic regarding the prospects for SAGE-217 in a placebo-controlled trial for MDD given the large effect size in the open-label (one said 75-80% chance of success)' We are now including risk-adjusted sales for SAGE-217 in MDD of $25mn in 2021 ramping up to $325mn in 2027. We partially offset that with some increased expenses; the net result was that our EPS changed by $(0.51)-4.04 in 2017-27, and our target goes to $82 from $68." (2/22/2017)
  • 3. Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • 4. Cowen and Company analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)
  • 5. Canaccord Genuity analysts commented, "We are encouraged by NDRM’s progress on its multiple development programs and continue to view the company’s approach to treating Parkinson’s disease as potentially paradigm-shifting. NDRM recently had an end of Ph2 meeting with the FDA to discuss ND0612 and has been allowed to move forward with PK equivalency in the US as opposed to doing a Ph3 efficacy trial. Additionally, NDRM announced positive top-line data from a pilot PK trial of ND0701 last week." (12/6/2016)

Who are some of Sage Therapeutics' key competitors?

Who are Sage Therapeutics' key executives?

Sage Therapeutics' management team includes the folowing people:

  • Kevin P. Starr, Independent Chairman of the Board
  • Jeffrey M. Jonas M.D., President, Chief Executive Officer, Director
  • Kimi E. Iguchi, Chief Financial Officer, Treasurer
  • Anne Marie Cook, Senior Vice President, General Counsel
  • Amy Schacterle Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Christopher Silber, Senior Vice President - Clinical Development
  • Albert J. Robichaud Ph.D., Chief Scientific Officer
  • Frank Sanders, Vice President of Sales and Marketing
  • Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
  • Thomas D. Anderson, Chief Commercial Strategy Officer

Who owns Sage Therapeutics stock?

Sage Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (8.12%), Vanguard Group Inc. (7.36%), Bank of New York Mellon Corp (5.32%), State Street Corp (3.24%) and Palo Alto Investors LLC (2.76%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Kevin P Starr, Kimi Iguchi and Stephen Kanes. View Institutional Ownership Trends for Sage Therapeutics.

Who sold Sage Therapeutics stock? Who is selling Sage Therapeutics stock?

Sage Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Marshall Wace North America L.P., Franklin Resources Inc., Oak Ridge Investments LLC, Artal Group S.A., Federated Investors Inc. PA, Bank of New York Mellon Corp and Palo Alto Investors LLC. View Insider Buying and Selling for Sage Therapeutics.

Who bought Sage Therapeutics stock? Who is buying Sage Therapeutics stock?

Sage Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Farallon Capital Management LLC, Pioneer Investment Management Inc., State Street Corp, Northern Trust Corp, Vanguard Group Inc., Quantitative Investment Management LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for Sage Therapeutics.

How do I buy Sage Therapeutics stock?

Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sage Therapeutics' stock price today?

One share of Sage Therapeutics stock can currently be purchased for approximately $62.90.


MarketBeat Community Rating for Sage Therapeutics (NASDAQ SAGE)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Sage Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $86.77 (37.95% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$117.00MediumView Rating Details
9/14/2017BMO Capital MarketsBoost Price TargetOutperform$80.00 -> $84.00HighView Rating Details
9/13/2017Chardan CapitalReiterated RatingHoldHighView Rating Details
9/13/2017Needham & Company LLCLower Price TargetBuy -> Buy$95.00 -> $86.00HighView Rating Details
9/13/2017Stifel NicolausReiterated RatingBuy$104.00 -> $91.00HighView Rating Details
9/13/2017SunTrust Banks, Inc.Reiterated RatingBuy$95.00 -> $82.00HighView Rating Details
9/12/2017Canaccord GenuityLower Price TargetBuy$110.00 -> $81.00HighView Rating Details
9/12/2017J P Morgan Chase & CoLower Price TargetOverweight$99.00 -> $85.00HighView Rating Details
9/12/2017Cowen and CompanyLower Price TargetOutperform$100.00 -> $90.00MediumView Rating Details
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00HighView Rating Details
6/20/2017Leerink SwannReiterated RatingOutperform$90.00 -> $97.00HighView Rating Details
5/12/2017Bank of America CorporationInitiated CoverageBuy -> Buy$85.00HighView Rating Details
12/14/2016Raymond James Financial, Inc.UpgradeOutperform -> Strong-Buy$84.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$63.00N/AView Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
Earnings by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Earnings History by Quarter for Sage Therapeutics (NASDAQ SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($1.63)($1.88)ViewListenView Earnings Details
5/9/2017Q1 2017($1.61)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
2017 EPS Consensus Estimate: ($6.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.58)($1.49)($1.54)
Q2 20173($1.64)($1.50)($1.56)
Q3 20173($1.70)($1.43)($1.58)
Q4 20173($1.70)($1.53)($1.59)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sage Therapeutics (NASDAQ:SAGE)
Insider Ownership Percentage: 6.10%
Insider Trades by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Insider Trades by Quarter for Sage Therapeutics (NASDAQ:SAGE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.00View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.00View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sage Therapeutics (NASDAQ:SAGE)
Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
Source:
DateHeadline
nasdaq.com logoImplied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock ... - Nasdaq
www.nasdaq.com - September 24 at 7:36 AM
finance.yahoo.com logoImplied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options
finance.yahoo.com - September 22 at 5:55 PM
finance.yahoo.com logoSage Therapeutics to Participate in Leerink Investor Conference
finance.yahoo.com - September 22 at 5:55 PM
benzinga.com logoSage Therapeutics Could Still Become A Leader In Neurology - Benzinga
www.benzinga.com - September 16 at 8:21 AM
finance.yahoo.com logoWhat to Expect from Sage Therapeutics’ Brexanolone
finance.yahoo.com - September 16 at 8:21 AM
finance.yahoo.com logoSage Therapeutics Could Still Become A Leader In Neurology
finance.yahoo.com - September 16 at 8:21 AM
finance.yahoo.com logoWhat Analysts Recommend for Sage Therapeutics
finance.yahoo.com - September 16 at 8:21 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 4:42 AM
americanbankingnews.com logoLeerink Swann Weighs in on Sage Therapeutics, Inc.'s FY2018 Earnings (SAGE)
www.americanbankingnews.com - September 15 at 1:46 PM
nasdaq.com logoSage Therapeutics Breaks Below 200-Day Moving Average - Notable for SAGE - Nasdaq
www.nasdaq.com - September 15 at 8:28 AM
benzinga.com logoJim Cramer Weighs In On Sage Therapeutics, FireEye And Palo Alto - Benzinga
www.benzinga.com - September 15 at 8:28 AM
americanbankingnews.com logoSunTrust Banks Research Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (SAGE)
www.americanbankingnews.com - September 15 at 8:26 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Research Coverage Started at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM
americanbankingnews.com logoWilliam Blair Comments on Sage Therapeutics, Inc.'s FY2018 Earnings (SAGE)
www.americanbankingnews.com - September 14 at 12:50 PM
benzinga.com logoSage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing
www.benzinga.com - September 14 at 9:39 AM
finance.yahoo.com logoSage Therapeutics Gets a Dunce Hat
finance.yahoo.com - September 14 at 9:39 AM
finance.yahoo.com logoIs Sage Therapeutics Inc (SAGE) Undervalued?
finance.yahoo.com - September 14 at 9:39 AM
finance.yahoo.com logoSage Shows Why There Are Rules for Drug Development
finance.yahoo.com - September 14 at 9:39 AM
finance.yahoo.com logoSage Dives On Seizure Trial, But Could Double On Depression Drugs
finance.yahoo.com - September 14 at 9:39 AM
finance.yahoo.com logoSage Therapeutics drug for rare condition deemed a failure, but company may see a path forward
finance.yahoo.com - September 14 at 9:39 AM
finance.yahoo.com logoCorporate News Blog - Sage Therapeutics Announces Top-Line Results from Phase-3 STATUS Trial of Brexanolone
finance.yahoo.com - September 14 at 9:39 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) PT Raised to $84.00
www.americanbankingnews.com - September 14 at 9:08 AM
americanbankingnews.com logo Brokerages Expect Sage Therapeutics, Inc. (SAGE) to Post -$1.94 EPS
www.americanbankingnews.com - September 14 at 4:16 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Stock Rating Reaffirmed by SunTrust Banks, Inc.
www.americanbankingnews.com - September 13 at 9:06 PM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - September 13 at 9:06 PM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - September 13 at 9:52 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Given New $86.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - September 13 at 9:52 AM
marketwatch.com logoSage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment - MarketWatch
www.marketwatch.com - September 13 at 8:40 AM
marketwatch.com logoSage Therapeutics drug for rare condition deemed a failure, but company may see a path forward - MarketWatch
www.marketwatch.com - September 13 at 8:40 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) PT Lowered to $13.70 at J P Morgan Chase & Co
www.americanbankingnews.com - September 12 at 7:36 PM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) PT Lowered to $81.00
www.americanbankingnews.com - September 12 at 7:36 PM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Price Target Lowered to $90.00 at Cowen and Company
www.americanbankingnews.com - September 12 at 12:34 PM
reuters.com logoBRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone
www.reuters.com - September 12 at 9:29 AM
nasdaq.com logoSage's seizure drug fails key trial, shares slump
www.nasdaq.com - September 12 at 9:29 AM
finance.yahoo.com logoSage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus
finance.yahoo.com - September 12 at 9:28 AM
finance.yahoo.com logoSage's seizure disorder drug fails late-stage trial
finance.yahoo.com - September 12 at 9:28 AM
finance.yahoo.com logo​Trial fail for Cambridge-based Sage casts doubt on lead drug
finance.yahoo.com - September 12 at 9:28 AM
finance.yahoo.com logoSage Therapeutics' stock sinks after disappointing late-stage trial of SRSE treatment
finance.yahoo.com - September 12 at 9:28 AM
finance.yahoo.com logoUS STOCKS-Wall St set to open higher as Irma weakens; Apple in focus
finance.yahoo.com - September 12 at 9:28 AM
finance.yahoo.com logoSage Therapeutics to Present at Morgan Stanley Healthcare Conference
finance.yahoo.com - September 8 at 7:53 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - September 1 at 2:16 PM
finance.yahoo.com logoOptions Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock
finance.yahoo.com - August 29 at 7:32 AM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Downgraded by BidaskClub
www.americanbankingnews.com - August 28 at 6:50 PM
americanbankingnews.com logoSage Therapeutics, Inc. (SAGE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:28 AM
americanbankingnews.com logoAnalyzing Sage Therapeutics (NASDAQ:SAGE) and Rosetta Genomics (ROSG)
www.americanbankingnews.com - August 9 at 12:24 PM
americanbankingnews.com logoStifel Nicolaus Begins Coverage on Sage Therapeutics, Inc. (SAGE)
www.americanbankingnews.com - August 9 at 7:40 AM
nasdaq.com logoSAGE October 20th Options Begin Trading - Nasdaq.com - Nasdaq
www.nasdaq.com - August 7 at 3:16 PM
americanbankingnews.com logoSAGE Therapeutics Inc (SAGE) Price Target Raised to $86.00
www.americanbankingnews.com - August 6 at 11:00 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Sage Therapeutics, Inc. (NASDAQ:SAGE) a $110.00 Price Target
www.americanbankingnews.com - August 6 at 8:56 AM
americanbankingnews.com logoSage Therapeutics' (SAGE) Buy Rating Reiterated at Cowen and Company
www.americanbankingnews.com - August 5 at 4:20 PM

Social

Chart

Sage Therapeutics (SAGE) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff